martes, 1 de abril de 2014

Menos mal que...vamos mal (XXIV), Annual Pharmaceutical Industry Audit: Enterprise Value

Click sobre imagen para ampliar

Gilead exhibited enterprise value growth of nearly 120 percent, followed by Actavis, at 101 percent, and Novo Nordisk, at slightly more than 38 percent. Gilead is a mainstay on the list for its record of operational efficiency, but also has benefited from the increasing mandated access to HIV medicines worldwide. Actavis is on an improvised, non-organic growth curve due its combination with Watson Pharmaceuticals in 2012, making it the world's third largest generic manufacturer, a record slated to be compounded further by the planned tie up with Warner-Chilcott. (Más)

Ver anterior:

Menos mal que...vamos mal (XXIII): Y se hicieron (bi)millonarios...

Publicar un comentario